Table 1. Patient, donor and GVHD characteristics.
| Patient and donor characteristics | ||||
|---|---|---|---|---|
| AML | ALL | CML | MDS | |
| Characteristics | N (%) | N (%) | N (%) | N (%) |
| Number of Patients (n=7489) | 2541 | 1798 | 2498 | 652 |
| Median recipient age at HCT, y (range) | 32 (<1-74) | 17 (<1-59) | 36 (1-66) | 37 (<1-65) |
| Age of recipient, years | ||||
| < 2 | 58 (2 ) | 58 (3 ) | 1 (<1) | 30 (5 ) |
| 2-17 | 541 (21) | 886 (49) | 233 (9 ) | 122 (19) |
| 18-29 | 561 (22) | 431 (24) | 551 (22) | 96 (15) |
| 30-39 | 512 (20) | 230 (13) | 768 (31) | 121 (19) |
| 40-49 | 565 (22) | 136 (8 ) | 673 (27) | 144 (22) |
| 50-59 | 281 (11) | 57 (3 ) | 259 (10) | 129 (20) |
| 60+ | 23 (<1) | 0 | 13 (<1) | 10 (2 ) |
| Gender | ||||
| Male | 1346 (53) | 1121 (62) | 1469 (59) | 359 (55) |
| Female | 1195(47) | 677(38) | 1029(41) | 293(45) |
| Disease status at HCT | ||||
| Early | 1518 (60) | 804 (45) | 2110 (84) | 229 (35) |
| Intermediate | 612 (24) | 862 (48) | 349 (14) | 6 ( 1) |
| Advanced | 411 (16) | 132 ( 7) | 39 ( 2) | 417 (64) |
| Graft source | ||||
| Bone Marrow | 1611 (63) | 1383 (77) | 1928 (77) | 434 (67) |
| Peripheral Blood | 930 (37) | 415 (23) | 570 (23) | 218 (33) |
| HLA match | ||||
| HLA-identical sibling | 1503 (59) | 810 (45) | 1284 (51) | 264 (40) |
| Well-matched unrelated | 445 (18) | 352 (20) | 434 (17) | 185 (28) |
| Partially matched unrelated | 368 (14) | 385 (21) | 486 (19) | 132 (20) |
| Mismatched unrelated | 225 ( 9) | 251 (14) | 294 (12) | 71 (11) |
| Donor-recipient gender match | ||||
| Male -> Male | 796 (31) | 675 (38) | 947 (38) | 246 (38) |
| Male -> Female | 640 (25) | 375 (21) | 551 (22) | 155 (24) |
| Female -> Male | 550 (22) | 446 (25) | 522 (21) | 113 (17) |
| Female -> Female | 555 (22) | 302 (17) | 478 (19) | 138 (21) |
| Donor-recipient CMV status | ||||
| Negative -> Negative | 727 (29) | 673 (37) | 791 (32) | 219 (34) |
| Negative -> Positive | 526 (21) | 316 (18) | 410 (16) | 139 (21) |
| Positive -> Negative | 313 (12) | 267 (15) | 328 (13) | 81 (12) |
| Positive -> Positive | 872 (34) | 483 (27) | 869 (35) | 189 (29) |
| Unknown | 103 ( 4) | 59 ( 3) | 100 ( 4) | 24 ( 4) |
| Median donor age, years (range) | 33 (<1-72) | 30 (<1-73) | 36 (<1-73) | 36 (<1-71) |
| HLA-identical sibling donor age, years, median (range) |
32 (<1-72) | 18 (<1-73) | 36 (<1-73) | 36 (<1-71) |
| HLA-identical sibling donor age, years | ||||
| < 10 | 135 (9 ) | 187 (23) | 32 (2 ) | 28 (11) |
| 10-17 | 181 (12) | 206 (25) | 86 (7 ) | 20 (8 ) |
| 18-29 | 360 (24) | 203 (25) | 269 (21) | 53 (20) |
| 30-39 | 330 (22) | 108 (13) | 388 (30) | 52 (20) |
| 40-49 | 297 (20) | 66 (8 ) | 326 (25) | 65 (25) |
| 50-59 | 140 (9 ) | 29 (4 ) | 124 (10) | 33 (13) |
| 60+ | 41 (3 ) | 4 (<1) | 31 (2 ) | 8 (3 ) |
| Missing | 19 (1 ) | 7 (<1) | 28 (2 ) | 5 (2 ) |
| Unrelated donor age, years, median (range) | 35 (19-60) | 35 (19-59) | 35 (18-65) | 35 (19-60) |
| Unrelated donor age, years | ||||
| 18-29 | 315 (30) | 284 (29) | 365 (30) | 104 (27) |
| 30-39 | 404 (39) | 367 (37) | 434 (36) | 151 (39) |
| 40-49 | 233 (22) | 234 (24) | 287 (24) | 97 (25) |
| 50-59 | 52 (5 ) | 57 (6 ) | 78 (6 ) | 20 (5 ) |
| 60+ | 2 (<1) | 0 | 2 (<1) | 1 (<1) |
| Missing | 32 (3 ) | 46 (5 ) | 48 (4 ) | 15 (4 ) |
| Donor parity prior to transplant | ||||
| Male donor | 1436 (57) | 1050 (58) | 1498 (60) | 401 (62) |
| Female, no pregnancy | 420 (17) | 380 (21) | 324 (13) | 78 (12) |
| 1 or more pregnancies | 473 (19) | 266 (15) | 483 (19) | 128 (20) |
| Missing | 212 ( 8) | 102 ( 6) | 193 ( 8) | 45 ( 7) |
| GVHD prophylaxis | ||||
| Ex vivo T-cell depletion | 246 (10) | 218 (12) | 204 ( 8) | 81 (12) |
| Cyclosporine ± methotrexate ± other | 1900 (75) | 1362 (76) | 2008 (80) | 472 (72) |
| Tacrolimus ± methotrexate ± other | 395 (16) | 218 (12) | 286 (11) | 99 (15) |
| ATG and/or alemtuzumab used | ||||
| None | 2131 (84) | 1399 (78) | 2088 (84) | 519 (80) |
| Yes | 312 (12) | 332 (18) | 318 (13) | 113 (17) |
| Missing | 98 ( 4) | 67 ( 4) | 92 ( 4) | 20 ( 3) |
| Total body irradiation use in the conditioning regimen | ||||
| No | 1314 (52) | 228 (13) | 1268 (51) | 379 (58) |
| Yes | 1227 (48) | 1570 (87) | 1230 (49) | 273 (42) |
| Year of transplant | ||||
| 1995-1999 | 1332 (52) | 1011 (56) | 1724 (69) | 351 (54) |
| 2000-2004 | 1209 (48) | 787 (44) | 774 (31) | 301 (46) |
| Prior aGVHD grade | ||||
| 0-I | 1537 (60) | 864 (48) | 1334 (53) | 317 (49) |
| II-IV | 1004 (40) | 934 (52) | 1164 (47) | 335 (51) |
| Median follow-up of survivors, months (range) | 80 (12 -179) | 80 (12 - 175) | 93 (12 -172) | 80 (12 - 168) |
| Chronic GVHD characteristics | ||||
|---|---|---|---|---|
| AML | ALL | CML | MDS | |
| cGVHD present at one-year after HCT | 1117/2541 (44%) |
742/1798 (41%) |
1344/2498 (54%) |
350/652 (54%) |
| Time from HCT to cGVHD months, (range) | 5 (1-11) | 5 (1-11) | 5 (1-11) | 5 (1-11) |
| Severity of cGVHD | ||||
| Mild | 485 (43) | 265 (36) | 425 (32) | 136 (39) |
| Moderate | 243 (22) | 159 (21) | 307 (23) | 67 (19) |
| Severe | 70 ( 6) | 48 ( 6) | 77 ( 6) | 14 ( 4) |
| Missing | 319 (29) | 270 (36) | 535 (40) | 133 (38) |
| Onset of cGVHD | ||||
| Progressive | 366 (33) | 306 (41) | 509 (38) | 130 (37) |
| Interrupted | 277 (25) | 204 (27) | 339 (25) | 96 (27) |
| De novo | 392 (35) | 179 (24) | 422 (31) | 91 (26) |
| Missing | 82 ( 7) | 53 ( 7) | 74 ( 6) | 33 ( 9) |
| Organ involvement | ||||
| Skin | 597 (53) | 445 (60) | 733 (55) | 189 (54) |
| Eyes | 331 (30) | 170 (23) | 401 (30) | 105 (30) |
| Mouth | 560 (50) | 331 (45) | 685 (51) | 173 (49) |
| Lung | 93 ( 8) | 53 ( 7) | 109 ( 8) | 34 (10) |
| GI | 217 (19) | 177 (24) | 273 (20) | 89 (25) |
| GU | 33 ( 3) | 12 ( 2) | 29 ( 2) | 13 ( 4) |
| Liver | 425 (38) | 213 (29) | 517 (38) | 122 (35) |
| Musculoskeletal | 59 ( 5) | 54 ( 7) | 110 ( 8) | 21 ( 6) |
| Hematologic | 109 (10) | 95 (13) | 138 (10) | 45 (13) |
| Number of organs involved in cGVHD | ||||
| 1 | 259 (23) | 195 (26) | 304 (23) | 82 (23) |
| 2 | 258 (23) | 177 (24) | 342 (25) | 74 (21) |
| 3 | 212 (19) | 127 (17) | 251 (19) | 59 (17) |
| 4 | 138 (12) | 76 (10) | 149 (11) | 49 (14) |
| 5 | 35 ( 3) | 21 ( 3) | 46 ( 3) | 15 ( 4) |
| 6 | 5 (<1) | 2 (<1) | 9 ( 1) | 2 ( 1) |
| Missing | 210 (19) | 144 (19) | 243 (18) | 69 (20) |
| KPS at diagnosis of cGVHD, n (%) | ||||
| <80 | 215 (19) | 154 (21) | 367 (27) | 90 (26) |
| 80-100 | 704 (63) | 453 (61) | 789 (59) | 173 (49) |
| Missing | 198 (18) | 135 (18) | 188 (14) | 87 (25) |
| Platelet count at diagnosis cGVHD ×109/L, n (%) | ||||
| <100 | 294 (26) | 214 (29) | 450 (33) | 95 (27) |
| ≥ 100 | 639 (57) | 409 (55) | 682 (51) | 183 (52) |
| Missing | 184 (16) | 119 (16) | 212 (16) | 72 (21) |
| Serum bilirubin at diagnosis of cGVHD mg/dL, n (%) | ||||
| < 1 | 665 (60) | 445 (60) | 638 (47) | 191 (55) |
| 1-2 | 152 (14) | 86 (12) | 311 (23) | 66 (19) |
| > 2 | 159 (14) | 117 (16) | 220 (16) | 37 (11) |
| Missing | 141 (13) | 94 (13) | 175 (13) | 56 (16) |